Impact Biomedical appoints Chan Heng Fai Ambrose to board of directors

IMPACT BIOMEDICAL INC.

Appointed March 11, 2025, effective same date; over 45 years financial/equity investment experience.
Current director/chair roles include Alset International, DSS Inc., Hapi Metaverse, LiquidValue Development, Alset Inc., Sharing Services Global, HWH International, Value Exchange International.
No arrangement or understanding with any other person for appointment; no family relationships or related-party transactions per Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Chan Heng Fai Ambrose

Director

IBO · IMPACT BIOMEDICAL INC.

Effective: 2025-03-11
Filed: March 13, 2025, 7:59 PM ET

On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chan Heng Fai Ambrose was appointed as Director at IMPACT BIOMEDICAL INC..

Action: appointed
Role: Director

Exact text from the filing

On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date.

View on SEC.gov

IMPACT BIOMEDICAL INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-010190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.